rates of resistance to 2 and to 3 classes of drugs were 5.9% and 7.7%. A phylogenetic analysis of 17 of 23 matched sequences of the samples with VLLV, for which a previous sequence was available when viremia was Ͼ1,000 copies/ml (Fig. 1) , allowed us to rule out cross-contamination. Moreover, every other month the G02 OptiQual HIV-1 genotype control (AcroMetrix Corporation) and the negative and positive control of the Trugene HIV-1 genotyping kit are routinely performed in the laboratory.
These findings suggest that, when a virologic failure is suspected for even minimal increases of HIV-1 RNA values, GRT can be performed with a high rate of success even in samples with VLLV, thus both enhancing the chance of sequencing the mutated virus and increasing the possibility of protecting against the occurrence of supplementary mutations.
The reasons why guidelines indicate HIV-1 RNA limits of Ͼ500 copies/ml for GRT lie in the alleged inconsistent feasibility of testing and reproducibility of results below that level (4, 5) . Only Italian guidelines recommend it for patients failing a cART with HIV-1 RNA values from 50 to 200 copies/ml (6). Our findings have the limitations of having been obtained from a relatively small series and with a kit that has been announced to be discontinued in the near future. However, by extending the results of other authors, they suggest that in clinical practice, the current methods for performing GRT are robust and efficient enough to deserve consideration even in the case of LLV and VLLV samples.
